Statin alternative awaits go-ahead
As Esperion Therapeutics awaited the US Food and Drug Administration's decision on its first-in-class drug, slated for 21 February, cardiologists welcomed trial evidence that the drug significantly reduces low-density lipoprotein cholesterol (LDL-C) in patients at high risk of cardiovascular disease. Esperion and investigators reported in JAMA the results from a phase 3 trial in 779 patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. At 12 weeks, the experimental drug bempedoic acid added to maximally tolerated statins lowered LDL-C by 15.1% from baseline, whereas in the control group of patients on background lipid-lowering therapy LDL-C level increased by 2.4%. In a pooled analysis of four pivotal trials, reported in November at the American Heart Association (AHA) meeting, bempedoic acid lowered LDL-C by 18% compared with placebo in patients on background statin therapy, and by 25% compared with placebo in statin-intolerant patients not on statin background therapy. A cardiovascular outcomes trial is ongoing, with results anticipated by 2022.
Bempedoic acid is an inhibitor of adenosine-citrate lyase, an enzyme in the lipid biosynthesis pathway that acts upstream of HMG-CoA reductase, the target of statins. It is under review with the FDA both as a monotherapy and as a combination tablet with generic lipidlowering agent ezetimibe, for patients with elevated LDL-C. Should it be approved, the oral drug will face a crowded market, dominated by cheap, convenient, generic statins. Esperion's agent will also compete with two approved subcutaneously injected PCSK9-targeted antibodies, which facilitate the clearance of LDL cholesterol from the blood. Sales of these antibodies have disappointed to date, in part due to their high cost. But Novartis acquired The Medicines Company in November over hopes for a PCSK9directed siRNA drug, currently under review at the FDA. An orally available bempedoic acid could shake things up further, especially if priced below PCSK9 modulators. Novartis and Akcea Therapeutics are also recruiting patients into a phase 3 trial of TQJ230, an antisense candidate that cuts lipoprotein(a) levels.
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Drugmakers turn sights on scarred lungs a 'master regulator' of fibrosis, pentraxin, is in drugmakers' sights, but drivers and mechanisms of the resulting remorseless and fatal lung disease remain unsolved. r oche is spending $1.4 billion to snap up a biotech company with a first-in-class drug candidate to treat fibrotic lungs. PRM-151, a recombinant version of the endogenous human protein pentraxin-2 pioneered by Promedior, has shown promising clinical activity in phase 2 studies, giving Roche another shot on goal as it faces looming competition for its idiopathic pulmonary fibrosis (IPF) small-molecule drug Esbriet (pirfenidone). Promedior's agent is part of a diverse and steadily maturing IPF pipeline, which is notable for the wide variety of mechanisms being explored (Table 1 ). The variety reflects the fact that much remains unknown about IPF and how best to tackle it. For patients, the approvals of Esbriet and of Boehringer Ingelheim's small molecule Ofev (nintedanib) have made a real difference, but new and better agents are still urgently needed. "The reality is our patients are still dying of respiratory failure, " says Toby Maher, professor of interstitial lung disease at Imperial College London and consultant respiratory physician at Royal Brompton Hospital.
IPF is a remorseless disease. It begins with an inflammatory phase, followed by a chronic fibrosis stage during which damaged epithelial cells in the tissue surrounding the alveoli (the lungs' air sacs) undergo apoptosis and are replaced by infiltrating pro-fibrotic fibroblasts, leading to a buildup of scar tissue and a fatal loss of lung function. Its precise triggers are unknown, but environmental toxins and genetic risk factors can predispose individuals to developing the condition. Even though the two approved drugs reduce the annual rate of decline in lung function by ~50% and lower the frequency of life-threatening acute exacerbations, they neither reverse nor halt the pathological process. Patients have median survival of three to five years a thoracic scan reveals pulmonary fibrosis, a fatal, age-associated lung disease characterized by irreversible lung scarring. Credit: James Cavallini/Science Source after diagnosis, but not everyone who has access to the current therapies, which are expensive, benefits. Up to a quarter of patients abandon the drugs because of intolerable gastrointestinal effects. Many others are on reduced and probably ineffective doses. "It's been demonstrated that lower-dose nintedanib and lowerdose pirfenidone do not work, " says Hans Schambye, CEO of Copenhagen, Denmark-based Galecto Biotech.
At the same time, the two approved drugs have helped to establish a regulatory pathway for the rest of the pipeline. They also represent the safety, efficacy and tolerability hurdles that other upcoming drugs must clear. However, their highly pleiotropic mechanisms are no great help in the hunt for would-be successors. Ofev was initially presented as an inhibitor for a select number of tyrosine kinase receptors, says Maher. "In reality, the therapeutic dose knocks out at least 12, if not more, tyrosine kinase receptors, " he says. Esbriet's mechanism is even more baffling. "Truth be told, we don't really have a clue about how it works, " he says. It is unclear, therefore, which signal pathways are the most important disease drivers. The ultimate causes are likely to differ from patient to patient. "It is probably several different diseases, with different characteristics, that are lumped together, " says Schambye. Modern diagnostic methods don't help to resolve these questions. As IPF is usually diagnosed on the basis of imaging data, tissue biopsies from patients are not routinely available for research. Although mouse models of lung fibrosis are available, they do not recapitulate all the effects of the human disease. The development of disease biomarkers is still at an early stage.
Despite all these challenges, researchers in academia and industry have amassed a wealth of preclinical evidence linking various targets with different aspects of the IPF pathology. One such target is pentraxin, a "master regulator" of fibrosis, according to Promedior's website. It appears to act in several ways: it prevents monocytes maturing into pro-fibrotic macrophages and fibrocytes, and it also inhibits the production of transforming growth factor-β (TGF-β), a cytokine long considered a key fibrosis mediator. Phase 2 data suggest PRM-151 could slow the rate of decline of lung function while largely preserving patients' performance in a six-minute walk test. The effect was particularly pronounced among patients who crossed over from the placebo to the drug-treatment group during an open-label extension phase of the study. "The data certainly, as presented, are interesting and suggestive of an effect, " says Maher. Not all of the data are consistent, he added. "I wouldn't bet all of my chips on it, " he cautions. "There's enough there to justify Roche having bought the drug. "
Other IPF drugs in development also appear to act in multiple ways. Galecto Biotech is pursuing an inhibitor of galectin-3, a lectin involved in cell-cell communication and signaling, which is now thought to be responsible for maintaining the fibrotic state, says Schambye. Initially, the company pursued its lead small-molecule drug TD139, a galectin inhibitor, because of its effects on TGF-β, says Schambye. A group led by Galecto cofounder Tariq Sethi (then of King's College London, now CSO at Nottingham, UK-based liquid biopsy firm Oncimmune) showed that both TGF-β and bleomyocininduced lung fibrosis were both markedly reduced in mice deficient in galectin-3. They also showed that IPF patients had elevated galectin-3 levels. "Galectin-3 in itself stimulates more galectin-3 secretion and activates TGF-β receptors, " he says. But later studies showed that galectin-3 also influences more targets considered relevant to IPF, including lysophosphatidic acid (LPA) and the pro-fibrotic signal molecules platelet-derived growth factor and connective tissue growth factor. The present trial in 450 patients is due to deliver data in 2021. "The FDA said it would be regarded as pivotal, " Schambye says. If positive, it would still probably require a second confirmatory trial for approval, he adds, although that may not be the case in Europe. "It may be possible to get conditional approval in Europe following a single trial. " LPA, which is released in response to lung cell injury, has been the target of several drug development efforts. It is elevated in the lungs of patients with IPF, and one of its receptors, the LPA 1 receptor, has been shown to mediate fibroblast recruitment in an animal model of IPF. Bristol-Myers Squibb has led the development of LPA 1 receptor antagonists. The company is now on its second clinical program in this area, after it halted development of an earlier molecule, BMS-986020, because of off-target safety issues unrelated to its mechanism. Mechelen, Belgium-based Galapagos is also targeting LPA signaling, by disrupting the activity of autotaxin, an extracellular enzyme that produces LPA from lysophosphatidylcholine, a phospholipid species present in plasma. LPA is generally not highly visible. "It is extremely tightly regulated -it has a half-life of a minute or so, " says Paul Ford, therapeutic area head, respiratory diseases, at Galapagos. In fibrosis, it becomes more abundant, however. The enabler is autotaxin, which is responsible not only for LPA production but also for a chaperone function, which provides LPA with an opportunity to interact with its receptors and to drive pro-fibrotic effects.
"It is this chaperone activity [that] we think is key, " says Ford. By disrupting it, Galapagos aims to shut down LPA signaling. Preliminary phase 2a data were encouraging. "What surprised us was the amount of responders, " says Ford. "At least three-quarters [of patients] look like they responded to the drug. " That level of response prompted Galapagos to move quickly to a pivotal phase 3 program, which is recruiting 1,500 participants. Top line data are due in early 2022, but the outcome of a futility analysis will be available in the first quarter of 2021.
"This is the only drug that targets injured epithelial cells and myofibroblasts." Sreerama Shetty, of the Texas Lung Injury Institute at the University of Texas Health Science Center, is spearheading the development of yet another approach, based on a peptide derived from caveolin-1, a membrane protein involved in the formation of caveolae, a type of lipid raft or region of the cell membrane with diverse functions in cell signaling. Shetty and co-workers recently reported that a seven-amino-acid fragment of a scaffolding domain in caveolin-1 demonstrated several antifibrotic effects in three different animal models of pulmonary fibrosis. The caveolin-1-derived peptide, CSP7, reduced production of extracellular matrix markers associated with fibrosis, it increased survival of alveolar epithelial cells, and it improved lung function. The researchers also saw similar effects in cells isolated from patients with end-stage IPF. The peptide appears to work by reversing the effects of p53 dysregulation in both alveolar epithelial cells and myofibroblasts (fibroblast-derived cells that participate in wound healing). "This is the only drug that targets injured epithelial cells and myofibroblasts, " says Shetty. "Unless there is distorted p53 expression, the peptide does not work. " Shetty is an adviser to Lung Therapeutics, which is testing the hypothesis in clinical trials by taking the peptide into clinical trials in IPF.
Not all of the industry's current pipeline will succeed. The IPF field is littered with many failures, including Biogen's recent casualty BG0001 (formerly STX-100), an α v β 6 integrin inhibitor it gained through its acquisition of Stromedix in 2012; Londonbased GlaxoSmithKline's inhaled smallmolecule α v β 6 integrin inhibitor GSK3008348; and several inhibitors of interleukin-13 or dual inhibitors of interleukin-4 and interleukin-13. A better understanding of the disease biology may help to guide future efforts more successfully; so too will the development of disease biomarkers.
Even as the clinical pipeline moves forward, preclinical research is uncovering new ideas that could underpin future drug classes. In Germany, Boehringer Ingelheim recently brought in-house a collaborative project with BioMed X Innovation Center,in Heidelberg, to pursue new drug targets associated with epigenetic regulation in lung fibroblasts and alveolar cells. It is no great surprise from a conceptual standpoint that IPF may have an epigenetic dimension. In general, epigenetics integrates signals from the environment and translates them into cellular phenotypes, says Renata Jurkowska, now of Cardiff University in Wales, who led the project while at BioMed X. "There are genome-wide methylation changes in IPF, " she says. Although she was unable to disclose specific details of the work with Boehringer, the project has opened up one more avenue through which to tackle this most difficult disease. ❐
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"If I was a newcomer, a researcher wishing to start gene-editing research and clinical trials, the case would be enough to alert me to the cost of such violations." Lu you, of Sichuan university in Chengdu, reacting the three-year prison sentence handed down in December to the Chinese scientist He Jiankui, creator of the world's first gene-edited babies. (Nature, 3 January 2020) "You can make that new animal, or you can wipe out that whole species. And if doing that turns out to have been a bad idea, it means you're going to have to deal with the consequences." alta Charo, professor of law and bioethics at the university of Wisconsin, Madison, discusses the dilemmas faced by researchers on gene drives as they become more efficient. (The New York Times Magazine, 8 January 2020) 
